Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Eli Lilly and Company
Pfizer
Kelonia Therapeutics, Inc.
Quetzal Therapeutics
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
Cellectar Biosciences, Inc.
Takeda
Cogent Biosciences, Inc.
Eli Lilly and Company
Kedrion S.p.A.
Ossium Health, Inc.
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Constellation Pharmaceuticals
Takeda
Cogent Biosciences, Inc.
Eli Lilly and Company
Novartis